Cargando…
Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182457/ https://www.ncbi.nlm.nih.gov/pubmed/30117118 http://dx.doi.org/10.1007/s40259-018-0297-y |
| _version_ | 1783362568525447168 |
|---|---|
| author | Webster, Christopher J. Woollett, Gillian R. |
| author_facet | Webster, Christopher J. Woollett, Gillian R. |
| author_sort | Webster, Christopher J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6182457 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-61824572018-10-22 Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?” Webster, Christopher J. Woollett, Gillian R. BioDrugs Letter to the Editor Springer International Publishing 2018-08-16 2018 /pmc/articles/PMC6182457/ /pubmed/30117118 http://dx.doi.org/10.1007/s40259-018-0297-y Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| spellingShingle | Letter to the Editor Webster, Christopher J. Woollett, Gillian R. Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?” |
| title | Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?” |
| title_full | Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?” |
| title_fullStr | Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?” |
| title_full_unstemmed | Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?” |
| title_short | Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?” |
| title_sort | comment on “the end of phase 3 clinical trials in biosimilars development?” |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182457/ https://www.ncbi.nlm.nih.gov/pubmed/30117118 http://dx.doi.org/10.1007/s40259-018-0297-y |
| work_keys_str_mv | AT websterchristopherj commentontheendofphase3clinicaltrialsinbiosimilarsdevelopment AT woollettgillianr commentontheendofphase3clinicaltrialsinbiosimilarsdevelopment |